The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of checkpoint inhibitor treatment-related cutaneous adverse events in racial and ethnic minority and Caucasian cohorts at Memorial Sloan Kettering Cancer Center.
 
Amaris Geisler
No Relationships to Disclose
 
Dulce M. Barrios
No Relationships to Disclose
 
Gregory Phillips
No Relationships to Disclose
 
Rosa Nouvini
No Relationships to Disclose
 
Mario E. Lacouture
Stock and Other Ownership Interests - OncoDerm (I)
Honoraria - ADC Therapeutics; Amgen; Apricity Health; AstraZeneca; azitra; azitra; Deciphera; Galderma; Genentech; Janssen; Johnson & Johnson; Kyowa Hakko Kirin; Loxo; Menlo Therapeutics; NCODA; Novartis; Novocure; OnQuality Pharmaceuticals; QED Therapeutics; Roche/Genentech; Seattle Genetics/Astellas; Teva; Teva
Consulting or Advisory Role - Abbvie; Adgero Biopharmaceuticals; Adjucare; Allergan; Amgen; Amryt Pharma; AstraZeneca; Bayer; Biotechspert; Boehringer Ingelheim; Celldex; Debiopharm Group; Dignitana; E.R. Squibb Sons, LLC; EMD Serono; Galderma; Genentech; Janssen Oncology; Janssen Research & Development; Johnson & Johnson; Legacy Healthcare Services; Legacy Healthcare Services; Lindi Skin; Lutris; Manner SAS; Menlo Therapeutics; Merck; Novartis; Novocure; OnQuality Pharmaceuticals; OurBrainBank; Parexel; Paxman; Pierre Fabre; QED Therapeutics; Roche; Roche; Roche; Roche; Seagen; Takeda/Millennium; Teva
Research Funding - Lutris; Novocure; Paxman; US Biotest; Veloce Pharmaceuticals
Travel, Accommodations, Expenses - AstraZeneca; Deciphera; Kyowa Hakko Kirin; Novocure; Teva
Other Relationship - OncoDerm (I)
(OPTIONAL) Uncompensated Relationships - OncoDerm; OncoDerm
 
Sarah Noor
No Relationships to Disclose